​

Crinetics Pharmaceuticals (CRNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRNX Stock Forecast

Crinetics Pharmaceuticals (CRNX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $84.86, with a high of $85.00 and a low of $84.00. This represents a 1.47% increase from the last price of $83.63.

$35 $45 $55 $65 $75 $85 High: $85 Avg: $84.86 Low: $84 Last Closed Price: $83.63

CRNX Stock Rating

Crinetics Pharmaceuticals stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (61.90%), 8 Hold (38.10%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 8 13 0 Strong Sell Sell Hold Buy Strong Buy

CRNX Price Target Upside V Benchmarks

TypeNameUpside
StockCrinetics Pharmaceuticals1.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts71120
Avg Price Target$80.71$81.91$85.80
Last Closing Price$83.63$83.63$83.63
Upside/Downside-3.49%-2.06%2.59%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 263131--17
Jun, 263121--16
May, 263111--15
Apr, 262111--14
Mar, 262111--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 28, 2026UBS$85.00$83.851.37%1.64%
Jul 08, 2026Alex ThompsonStifel Nicolaus$85.00$83.501.80%1.64%
Jul 08, 2026Evercore ISI$85.00$83.531.76%1.64%
Jul 07, 2026Jefferies$85.00$42.03102.24%1.64%
Jul 07, 2026H.C. Wainwright$85.00$42.03102.24%1.64%
Jul 07, 2026Robert W. Baird$85.00$42.03102.24%1.64%
Jul 02, 2026Ashwani VermaUBS$55.00$38.6842.19%-34.23%
Jun 22, 2026Alex ThompsonStifel Nicolaus$83.00$36.06130.17%-0.75%
Jun 15, 2026Douglas TsaoH.C. Wainwright$81.00$34.47134.99%-3.14%
May 15, 2026Gavin Clark-GartnerEvercore ISI$88.00$37.71133.36%5.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 28, 2026UBSBuyNeutraldowngrade
Jul 07, 2026Cowen & Co.Holddowngrade
Jul 07, 2026CitigroupMarket OutperformMarket Performdowngrade
Jul 07, 2026JefferiesHolddowngrade
Jul 07, 2026Piper SandlerOverweightNeutraldowngrade
Jul 07, 2026H.C. WainwrightBuyNeutraldowngrade
Jul 07, 2026OppenheimerOutperformPerformdowngrade
Jul 07, 2026Cantor FitzgeraldOverweightNeutraldowngrade
Jul 06, 2026Goldman SachsBuyBuyupgrade
Jul 02, 2026UBSNeutralBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.15$-3.69$-3.69$-4.95---
Avg Forecast$-3.16$-3.63$-3.69$-3.87$-4.23$-3.16$-0.51
High Forecast$-0.90$-3.54$-3.57$-3.35$-2.28$-1.92$-0.13
Low Forecast$-11.13$-3.78$-3.94$-5.00$-5.65$-4.38$-1.72
Surprise %-0.32%1.65%-27.91%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.74M$4.01M$1.04M$5.42M---
Avg Forecast$4.26M$4.23M$1.60M$6.42M$48.29M$209.55M$519.02M
High Forecast$12.51M$4.93M$2.35M$16.81M$48.29M$594.86M$1.47B
Low Forecast$1.91M$3.93M$1.41M$2.54M$48.29M$89.73M$222.24M
Surprise %11.21%-5.12%-34.91%-15.62%---

Net Income Forecast

$-650M $-520M $-390M $-260M $-130M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-163.92M$-214.53M$-298.41M$-465.32M---
Avg Forecast$-183.75M$-214.53M$-218.09M$-242.43M$-230.34M$-182.92M$-29.47M
High Forecast$-52.17M$-205.73M$-207.46M$-194.27M$-132.55M$-111.27M$-7.56M
Low Forecast$-646.59M$-219.56M$-228.72M$-290.60M$-328.12M$-254.58M$-99.92M
Surprise %-10.79%-36.83%91.94%---

CRNX Forecast FAQ

Is Crinetics Pharmaceuticals stock a buy?

Crinetics Pharmaceuticals stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Crinetics Pharmaceuticals is a favorable investment for most analysts.

What is Crinetics Pharmaceuticals's price target?

Crinetics Pharmaceuticals's price target, set by 21 Wall Street analysts, averages $84.86 over the next 12 months. The price target range spans from $84 at the low end to $85 at the high end, suggesting a potential 1.47% change from the previous closing price of $83.63.

How does Crinetics Pharmaceuticals stock forecast compare to its benchmarks?

Crinetics Pharmaceuticals's stock forecast shows a 1.47% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Crinetics Pharmaceuticals over the past three months?

  • July 2026: 17.65% Strong Buy, 76.47% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 18.75% Strong Buy, 75.00% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.00% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is Crinetics Pharmaceuticals’s EPS forecast?

Crinetics Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.23, marking a -14.55% decrease from the reported $-4.95 in 2025. Estimates for the following years are $-3.16 in 2027, and $-0.51 in 2028.

What is Crinetics Pharmaceuticals’s revenue forecast?

Crinetics Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $48.29M, reflecting a 790.96% increase from the reported $5.42M in 2025. The forecast for 2027 is $209.55M, and $519.02M for 2028.

What is Crinetics Pharmaceuticals’s net income forecast?

Crinetics Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-230M, representing a -50.50% decrease from the reported $-465M in 2025. Projections indicate $-183M in 2027, and $-29.471M in 2028.